Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00005660 · ClinicalTrials.gov registry record
The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases
A clinical trial, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- 130
- Enrollment target
NCT00005660: Completed study, sponsored by National Cancer Institute (NCI).
NCT00005660 is a clinical trial that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 130 participants. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT00005660 has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- 130 participants
- Enrollment target
Study Summary
This is a continuing study which evaluates the long-term safety and efficacy of oral acitretin in an open manner in the treatment of psoriasis, cutaneous disorders of keratinization, multiple basal cell carcinomas and other retinoid responsive diseases.
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 130 participants |
| Start Date | 1977-10 |
| Est. Completion | 2001-11 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00005660
The ClinicalTrials.gov registry entry for NCT00005660 describes a study currently listed as completed, categorized as an unspecified phase. The registered enrollment target is 130 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 0 interventions.
NCT00005660 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT00005660 about?
NCT00005660 is a clinical study titled "The Evaluation of Oral Acitretin in the Treatment of Psoriasis, Cutaneous Disorders of Keratinization, Multiple Basal Cell Carcinomas and Other Retinoid Responsive Diseases". This is a continuing study which evaluates the long-term safety and efficacy of oral acitretin in an open manner in the treatment of psoriasis, cutaneous disorders of keratinization, multiple basal cell carcinomas and other retinoid responsive diseases.
What is the current status of trial NCT00005660?
This trial is currently completed. The enrollment target is 130 participants. The study started on 1977-10. Estimated completion is 2001-11.
Who is sponsoring clinical trial NCT00005660?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, the data changelog, or report a data error.